New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 8, 2014
09:23 EDTHPTXHyperion Therapeutics should be bought on any weakness, says JMP Securities
After sales of Hyperion's Ravicti beat expectations in Q2 but the company disclosed a delay in the initiation of its planned Phase 3 hepatic encephalopathy program for Ravicti, JMP Securities thinks any weakness in the stock is a buying opportunity for investors with a long-term focus, and/or an appreciation for the potential value of the company's diabetes program. The firm notes that Phase 3 data for the drug is expected in 1Q15 and keeps an Outperform rating.
News For HPTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 26, 2015
08:43 EDTHPTXHyperion Therapeutics management to meet with Needham
Meetings to be held in Detroit/Chicago on March 31 and in Chicago on April 1 hosted by Needham.
March 25, 2015
11:01 EDTHPTXHyperion Therapeutics price target raised to $51 from $40 at Brean Capital
Subscribe for More Information
March 23, 2015
11:16 EDTHPTXHyperion Therapeutics price target raised to $52 from $36 at Wedbush
Wedbush raised Hyperion's price target to $52 ahead of the hepatic encephalopathy Phase III trial of Ravicti and the likelihood of success. Shares are Outperform rated.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use